Cabozantinib (Cabometyx®) in combination with nivolumab (Opdivo®) for 1L RCC. HTA ID: 22018
Cabozantinib (Cabometyx®), in combination with nivolumab (Opdivo®), is indicated for the first-line treatment of advanced renal cell carcinoma in adults.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 28/03/2022 |
| Rapid review completed | 11/05/2022 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cabozantinib (Cabometyx®) in combination with nivolumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |